Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma,…
| Métrica | NANO.PA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | -36.5% | -34.4% | -2.1% |
| Net Margin | -80.8% | -32.5% | -48.4% |
| FCF Margin | -114.6% | -12.6% | -102.0% |
| ROE | — | -39.2% | — |
| ROA | -35.4% | -30.9% | -4.4% |
| Current Ratio | 1.09 | 2.73 | -1.64 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -35.4% | — |
| ✗Flujo de caja operativo positivo | −€33M | −€20M |
| ✓Rentabilidad sobre activos al alza | -35.4% | -101.1% |
| ✗Caja operativa/activos supera al ROA | -49.3% | ROA -35.4% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.09 | 1.04 |
| ✗Sin aumentar el nº de acciones | 48M | 47M |
| –Margen bruto al alza | — | — |
| ✓Rotación de activos al alza | 0.44 | -0.17 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -114.6% |
| ✗ROCE > 10 % | -105.5% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 79.8% |
NANOBIOTIX cotiza a 19.12 EUR y tiene una capitalización bursátil de €974M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud